CMC4

Across TCGA pan-cancer cohorts, CMC4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CMC4 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CMC4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CMC4 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where CMC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.603	0.874	<.001	35	view →
HNSC	OS	Median	III,IV	0.449	1.000	.023	20	view →
UCEC	DFS	Quartile	All	0.883	1.000	.037	6	view →
PDAC	OS	Tertile	All	0.974	0.668	.015	5	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CMC4–CCRCC (DFS)

Open the CCRCC breakdown →